Moderna (MRNA)
(Delayed Data from NSDQ)
$77.40 USD
-0.19 (-0.24%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $77.26 -0.14 (-0.18%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth D Momentum F VGM
Brokerage Reports
Moderna, Inc. [MRNA]
Reports for Purchase
Showing records 221 - 240 ( 262 total )
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
Impact from COVID-19 Puts Even More Focus on Vaccines
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
Market Shudders But We See Names to Outperform.
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
Reports Positive Pivotal Interim Results with VB-111 in Ovarian Cancer
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
Coronavirus Vol. 10: Review of 294 Global COVID19 Trials
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
Meet Our COVID-19 Drug Developers Call Series
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - Coronavirus Vol. 7: Our COVID-19 Trial Tracker - Numbers on Silent Carriers
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
Coronavirus Note, Vol.3: Testing Grows as More Diagnostics Come Online
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
Yas'' Weekly Recap of Our Key Notes and 19 Doc Calls Upcoming in 1H20
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
Takeaways from Our Deep Dive mRNA Vaccine Call with Mgmt
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
Coronavirus Crisis Update- Infections Moving West
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
Yas'' Weekly Recap of Our Key Notes and 8 Doc Calls Upcoming in 1H20
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
4Q19 - Prophylactics Are the Golden Ticket Going Forward for MRNA
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
Dial in Friday to Hear Why MRNA''s Prophylactic Vaccines Are the Chosen Few
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y